Fate Therapeutics Inc FATE
We take great care to ensure that the data presented and summarized in this overview for FATE THERAPEUTICS INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding FATE
View all-
Redmile Group, LLC San Francisco, CA13.2MShares$17.1 Million3.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.4MShares$13.5 Million0.0% of portfolio
-
Black Rock Inc. New York, NY10.1MShares$13.2 Million0.0% of portfolio
-
Deep Track Capital, LP Greenwich, CT5.57MShares$7.24 Million0.72% of portfolio
-
State Street Corp Boston, MA5.25MShares$6.83 Million0.0% of portfolio
-
Boxer Capital, LLC San Diego, CA4.96MShares$6.45 Million0.92% of portfolio
-
Bellevue Group Ag Kuesnacht, V84.84MShares$6.29 Million0.29% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il4.28MShares$5.57 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY3.56MShares$4.62 Million0.23% of portfolio
-
Johnson & Johnson New Brunswick, NJ3.38MShares$4.39 Million3.77% of portfolio
Latest Institutional Activity in FATE
Top Purchases
Top Sells
About FATE
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell lymphoma and chronic lymphocytic leukemia; FT538 to treat AML and multiple myeloma; FT576 to treat multiple myeloma; FT819 to treat hematologic malignancies and solid tumors; FT536 to treat solid tumors; and FT500 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Insider Transactions at FATE
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 15
2025
|
Jerome Charles Bressi |
BUY
Grant, award, or other acquisition
|
Direct |
65,000
+16.24%
|
-
|
|
Jan 15
2025
|
Cindy Tahl |
BUY
Grant, award, or other acquisition
|
Direct |
70,000
+14.68%
|
-
|
|
Jan 10
2025
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
5,654
-1.65%
|
$5,654
$1.55 P/Share
|
|
Jan 10
2025
|
Jerome Charles Bressi |
SELL
Open market or private sale
|
Direct |
5,980
-2.17%
|
$5,980
$1.55 P/Share
|
|
Jan 10
2025
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
8,705
-2.43%
|
$8,705
$1.54 P/Share
|
|
Dec 20
2024
|
Redmile Group, LLC Director |
BUY
Open market or private purchase
|
Indirect |
397,964
+3.0%
|
$397,964
$1.68 P/Share
|
|
Dec 20
2024
|
Redmile Group, LLC Director |
SELL
Open market or private sale
|
Indirect |
341,633
-2.66%
|
$341,633
$1.68 P/Share
|
|
Dec 20
2024
|
Redmile Group, LLC Director |
BUY
Other acquisition or disposition
|
Indirect |
1,084,936
+7.8%
|
$1,084,936
$1.68 P/Share
|
|
Dec 20
2024
|
Redmile Group, LLC Director |
SELL
Other acquisition or disposition
|
Indirect |
1,084,936
-8.46%
|
$1,084,936
$1.68 P/Share
|
|
Dec 12
2024
|
Redmile Group, LLC Director |
BUY
Conversion of derivative security
|
Indirect |
30,110
+0.23%
|
-
|
|
Aug 06
2024
|
Yuan Xu |
SELL
Open market or private sale
|
Direct |
633
-6.81%
|
$2,532
$4.23 P/Share
|
|
Jul 29
2024
|
Bahram Valamehr President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+35.84%
|
-
|
|
Jul 29
2024
|
Cindy Tahl |
BUY
Grant, award, or other acquisition
|
Direct |
200,000
+36.88%
|
-
|
|
Mar 04
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,447
-2.35%
|
$17,129
$7.77 P/Share
|
|
Jan 29
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,849
-1.75%
|
$9,245
$5.0 P/Share
|
|
Jan 09
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
7,028
-6.23%
|
$28,112
$4.37 P/Share
|
|
Jan 09
2024
|
J Scott Wolchko President and CEO |
SELL
Open market or private sale
|
Direct |
14,391
-3.73%
|
$57,564
$4.37 P/Share
|
|
Jan 09
2024
|
Bahram Valamehr President and CEO |
SELL
Open market or private sale
|
Direct |
11,271
-6.66%
|
$45,084
$4.38 P/Share
|
|
Jan 09
2024
|
Cindy Tahl |
SELL
Open market or private sale
|
Direct |
10,874
-7.1%
|
$43,496
$4.37 P/Share
|
|
Jan 02
2024
|
Edward J Dulac Iii Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,182
-4.39%
|
$15,546
$3.66 P/Share
|
Last 12 Months Summary
| Conversion of derivative security | 30.1K shares |
|---|---|
| Other acquisition or disposition | 1.08M shares |
| Open market or private purchase | 398K shares |
| Grant, award, or other acquisition | 535K shares |
| Other acquisition or disposition | 1.08M shares |
|---|---|
| Open market or private sale | 365K shares |